Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
1 Feb, 2019 (Friday)

            
GCL-POLY ENERGY(3800)
Analysis:
The polysilicon production plant of GCL-Poly Energy Holdings (3800) in Xinjiang Uyghur Autonomous Region, the PRC has officially commenced trial production and the production capacity of the newly-built facilities is 60,000 tonnes. With the low electricity cost in Xinjiang Uyghur Autonomous Region, the plant may become the world`s leading low-cost, high-quality polysilicon production base. Separately, the Group`s technical transformation of diamond-wire sawing polysilicon wafers was completed at the end of 2017. As a result, the production cost of wafer is expected to further decrease in the future.The profitability of the Group will greatly improve this year. (I do not hold the above stock)
Strategy:
Buy-in Price: $0.60, Target Price: $0.70, Cut Loss Price: $0.55

UM HEALTHCARE(2138)
Analysis:
The Group is principally engaged in the provision of medical, quasi- medical, traditional beauty services, the sale of skincare and beauty products. For the six months ended 30 September, according to the interim results, the revenue of the Group was HKD 853 million, up 38.2% YoY; the net profit was 203 million HKD, up 61% YoY. The Group entered into agreement with “Tencent Doctorwork”, a subsidiarity of Tencent last year, for jointly establishing primary care clinics in Hong Kong and co-invest and developing IT system to connect medical services across the PRC and Hong Kong. Besides, they plan to establish a total of 20 clinics in Hong Kong over the next three years. Currently, two clinics under the brand 企鵝醫生 have commenced operation in Hong Kong. In addition, thanks to the promotion of the “Greater Bay Area”, the medical tourism becomes a growth driver. The revenue from PRC clients increased by 48.5% to HK$327.3 million, representing 38.4% of the total revenue. In the future, the Group will continue the expansion of their medical aesthetic clinic in first-tier and selected second-tier cities in the PRC, and explore acquisition targets as well as partnership opportunities with local medical players in the PRC.
Strategy:
Buy-in Price: $5.00, Target Price: $6.50, Cut Loss Price: $4.50


Geely (175.HK) - Short-term slowdown and long-term growth potential

Investment Summary

We expect that in 2019, although the growth rate of car sales of the company is unlikely to repeat the high growth rate of 40-50% in previous years, it is promising that the company enters a new stage of development in terms of model structure, selling price of single vehicles and gross profit growth of single vehicles after this adjustment. As the new products and capacity release progress steadily and the company's medium- and long-term growth is promising. So, we maintain the rating of Buy.

Voluntary de-inventory at the end of the year, and Dec sales fell by 40%.

Because of the higher base in the same period of last year, the economic sentiment index chilled the car market. Besides the fact that the company's new main car models have not yet developed and the old models are challenged by the sinking price caused by the competition among the joint venture brands. Although Geely's month-on-month sales have remained basically stable, year-on-year growth ratio has narrowed monthly from the third quarter, and the fourth quarter even fell to single-digit. Geely's inventory index of its brand dealers has exceeded 2.0 in July/October/November, reaching 2.4/2.8/2.3. In December, in order to reduce the inventory pressure of dealers, the company took the initiative to reduce wholesale sales volume to 93,000 vehicles, down sharply 39% on a month-on-month basis, reaching new lows in 16 months and reflected the company's firm intention to take the initiative to de-inventory.

Sales increased by 20% in 2018, and the sales structure moved up

In 2018, the company sold 1,500,838 vehicles, a year-on-year increase of 20% or 253,722 units. Although it did not reach the target of 1.58 million vehicles at the beginning of the year, the growth rate was still noticeable in the industry. On a closer look of vehicle models, the main contribution of sales increment came from the new type Vision X3 (+85,711 units)/S1 (+57,243 units), LYNK&CO 01 (+83,393 units), and the newly launched Borui GE (+24,803 units), LYNK&CO 02 (+21,751 units), Binrui (+33,084 units), Binyue SUV (+23,361 units), and the older model Emgrand GL (+24,419 units). Sales decrement mainly came from older Bo Yue SUV (-31,190 units), low-end model Emgrand (-17,499 units), Vision SUV and KingKong. The succession of the new to the old in vehicle sales was still evident, and the structure of the car models moved up.

MGMT holds a conservative 2019 sales target, to slow down the pace for a long-term development

The sales target for 2019 set by the management of Geely is 1.51 million vehicles, remaining unchanged compared with that of 2018. In 2019, the company's efforts to promote new models remain unchanged. In addition to the upgraded versions of existing models such as new Bo Yue/Emgrand and PHEV versions of existing models, Geely will launch 5-6 types of brand-new models, including two MPV models Jia Ji and VF12, coupe FY11, EV GE11, a brand-new medium SUV "SX12" from BMA platform, and a new model of LYNK&CO.

It is worth mentioning that 2019 will be the year when Geely's new energy strategy is fully launched. New energy and electrified versions of various models will be launched one after another, including LYNK&CO 02/03 PHEV, Binyue PHEV, Jia Ji PHEV, and FY11PHEV. New energy and electrified vehicles accounted for 67,919 of the total sales in 2018, up 173% Y-o-Y, accounting for 4.5% of the total sales. With the accelerated introduction of PMA platform vehicles, the proportion of new energy vehicles will gradually increase in the future.

Investment Thesis

We expect that in 2019, although the growth rate of car sales of the company is unlikely to repeat the high growth rate of 40-50% in previous years, it is promising that the company enters a new stage of development in terms of model structure, selling price of single vehicles and gross profit growth of single vehicles after this adjustment. To reflect the lasted forecast and valuation, we revised our target price to HK$17.6, equivalent to 10.9/10.5 P/E ratio in 2018/2019, and we maintain the rating of Buy. (Closing price as at 30 Jan 2019)

Financials

Click Here for PDF format...




Recommendation on 1-2-2019
RecommendationBuy
Price on Recommendation Date$ 12.660
Suggested purchase priceN/A
Target Price$ 17.600
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.